Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04544709
Other study ID # IRB 117455
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date February 14, 2019
Est. completion date July 29, 2022

Study information

Verified date December 2023
Source University of Utah
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess changes in pain and function in patients with discogenic low back pain after a standard of care intradiscal injection of Platelet-Rich Plasma (PRP).


Description:

Low back pain is one of a few conditions which affects all individuals through the lifespan. The etiology of low back pain is multifactorial and in many cases self-limiting, however it also is the leading cause for working age adults to be disabled with more than $87 billion spent on low back pain disorders in 2013 Lumbar disc herniation and internal disc disruption are two causes more common in these younger age groups reaching 39-42% with a predicted probability above 60% until age 50y. While the natural history of disc herniation suggests most individuals will return to a prior level of function in 3-6 months, there is a high rate of recurrent episodes which can cause short-term disability. Continued pain from a discogenic source can lead to decreased activity levels and accelerate degenerative changes in the disc and facet joints as described by Kirkaldy-Willis. Current guidelines for treatment of axial low back pain from discogenic sources including those with radiculopathy include a 6-12-week course of conservative care including medications, therapy, acupuncture, chiropractic and exercise before an interventional paradigm of injections and/or surgical treatment. For those individuals who do not improve with conservative care and have predominately axial pain, options are limited as success rates from epidural steroid injections and surgery are 50% or less. Other treatments include chymopapain injection, intradiscal electrothermal annuloplasty (IDET), nucleoplasty, methylene blue injection, ozone injection , fibrin sealant injections. All of which have 50% or less likelihood of reducing pain more than 50%, although much of this data is from uncontrolled or prospective case-control studies only. Platelet- rich plasma (PRP) injections stand apart from those listed above in that they are purported to be "regenerative" interventions for the diseased lumbar disc. PRP is a concentrated injectant of growth factors and anabolic factors which have in vitro and animal studies that have demonstrated upregulated proteoglycan synthesis and nucleus pulposus proliferation, restoration of disc height, healing of annular puncture wounds and anti-inflammatory effect with down regulation of TNF-alpha and IL-1. There has been limited clinical trials in humans on the effect of intradiscal PRP, including 3 trials of which 1 is a RCT and 2 are prospective series. Efficacy of intra-discal injection has shown statistically significant benefits in reduction in pain, improvement in physical function at follow-up points from 3-24 months. Each of these trials have limited sample sizes, short duration follow-up and lack of a standardized PRP preparation, making the generalizability difficult.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date July 29, 2022
Est. primary completion date July 29, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age greater than 18 years of age at day of enrollment. 2. Clinical diagnosis of refractory discogenic low back pain for >3 months. 3. Magnetic resonance imaging pathology consistent with clinical symptoms/signs or positive lumbar provocative discography according to SIS/IASP standards at one or two levels. 4. Back pain greater than leg pain with an intensity of at least 4/10 or higher using the Numerical Rating Scale (NRS). 5. Pain duration of more than 12 weeks despite trial of conservative therapy (medications, physical therapy, or chiropractic care) for 2 months. Exclusion Criteria: 1. Refusal to participate, provide consent, or provide follow-up information for the 24-month duration of the study. 2. Contraindications to intradiscal injection of PRP (active infection, bleeding disorders, current anticoagulant or antiplatelet medication use, allergy to iodinated contrast, penicillin or clindamycin and pregnancy or breastfeeding). 3. More than 2 levels of clinical or discogram proven pain. 4. Non-discogenic source of low back pain as identified by separate diagnostic blocks. 5. Negative lumbar provocation discography. 6. Active moderate to severe lumbar radiculopathy. 7. Intradural disc herniation. 8. Spinal fracture within the past 6 months. 9. Steroid injection in the spine within the last 30 days. 10. Any intradiscal injection other than contrast dye or anesthetic in the last 30 days. 11. Prior fusion at level considered to be the source of the pain. 12. Prior lumbar spine surgery within the last 6 months. 13. AP diameter of spinal canal less than or equal to 9mm at level to be treated. 14. Severe uncontrolled medical condition. 15. Moderate to severe hepatic dysfunction. 16. Severe psychological illness. 17. History of Inflammatory arthritis. 18. Malignancy within past 5 years except basal cell or squamous cell skin cancer. 19. Current use of equal to greater than 30mg morphine-equivalent per day of opioid use. 20. A history of alcohol or drug abuse within past 5 years. 21. Use of any investigational drug within past 30 days. 22. A known allergy or sensitivity to citrate (used for processing PRP). 23. Severe anaphylactic/anaphylactoid reaction to any medications used. 24. Pending litigation involving subject's back pain. 25. No insurance coverage for any subsequent tests or procedures. 26. Disc protrusion greater than 5mm from base of vertebral body. 27. Greater than 50% disc height loss at involved level(s). 28. Inability or unwillingness to continue rehabilitation protocols.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Low back intradiscal injection of platelet rich plasma (PRP)
SOC Intradiscal Lumbar PRP Procedure : A small amount of blood is drawn from you, then it is spun in a centrifuge to obtain only the platelets and few other cells. After being spun the small amount of platelets will be injected into the specific disc that is believed to be causing pain in an attempt to help reduce inflammation and pain at the site. The injection will be done under fluoroscopic guidance (x-ray) that allows very careful and precise placement of the needle.

Locations

Country Name City State
United States University of Utah Orthopaedic Center Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
University of Utah

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Numeric Rating Scale for Low Back Pain at 2-Month Follow-up Proportion of participants with =80% and =50% reductions from baseline in 7-day average low back pain intensity scores on the Numeric Rating Scale (NRS) at the 2-month follow-up assessment. 2 months
Secondary Median Change in Low Back Pain Numeric Rating Scale (NRS) Score The Numeric Rating Scale (NRS) was used to quantify low back pain by asking patients to rate their pain intensity on an 11-point scale ranging from 0 to 10, with 0 representing "no pain at all" and 10 representing "the worst pain imaginable". NRS change scores were calculated by subtracting baseline scores from follow-up scores, so that negative change scores correspond to decreases in low back pain. 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 24 months, 36 months
Secondary Proportion of Patients With =30% Improvement From Baseline on the Oswestry Disability Index (ODI) The Oswestry Disability Index (ODI) is an instrument used in clinical and research applications to quantify disability due to low back pain as a percentage score based on patients' self-reported level of function in activities of daily living. 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 24 months, 36 months
Secondary Proportion of Patients With a =6 Score on Patient Global Impression of Change (PGIC) Patient Global Impression of Change is a scale which measures participant reported satisfaction after an intervention. The outcome was measured as the percent of patients reporting a PGIC score of 6-7 (indicating "much improved" and "very much improved"). 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 24 months, 36 months
Secondary Proportion of Patients With a Medication Quantification Scale (MQS) III Score Reduction From Baseline of =6.8 Points A score of 6.8 points on the MQS III is equivalent to approximately 10 daily morphine equivalents 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 24 months, 36 months
Secondary Oswestry Disability Index (ODI) Change Scores The Oswestry Disability Index (ODI) is an instrument used in clinical and research applications to quantify disability due to low back pain as a percentage score (0-100%) based on patients' self-reported level of function in activities of daily living, with higher scores indicating greater disability. ODI change scores were calculated by subtracting baseline scores from follow-up scores, so that negative change scores correspond to functional improvements. 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 24 months, 36 months
Secondary PROMIS PF CAT Change Scores Patient-Reported Outcomes Measurement Information System Physical Function Computerized Adaptive Testing (PROMIS PF CAT) measures limitations of physical activity on a scale of 0 to 100, with higher scores indicating fewer limitations. PROMIS PF CAT change scores were calculated by subtracting baseline scores from follow-up scores, so that positive change scores represent improvements to functional limitations. 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 24 months, 36 months
Secondary Pain and Sleep Questionnaire 3-Item Index (PSQ-3) Change Scores The 3-Item Pain and Sleep Questionnaire is an instrument used in clinical and research applications to measure the impact of pain on sleep in chronic pain populations. A higher total score (range 0 to 300) indicates a greater extent of pain-related sleep interference. PSQ-3 change scores were calculated by subtracting baseline scores from follow-up scores, so that negative change scores correspond to reductions in pain-related sleep interference. 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 24 months, 36 months
Secondary Patient Satisfaction Scores The Patient Satisfaction Score represents patient satisfaction with the healthcare received using a five-point Likert scale where 1 = "very dissatisfied"; 2 = "dissatisfied"; 3 = "neither satisfied nor dissatisfied"; 4 = "satisfied"; and 5 = "very satisfied". 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 24 months, 36 months
Secondary Patient Global Impression of Change (PGIC) Scores Patient Global Impression of Change (PGIC) scores represent participants' overall satisfaction after an intervention. Participants are asked to rate their perception of change on a scale of 1 to 7, where 1="very much worse", 2="much worse", 3="worse", 4="no change", 5="improved", 6="much improved", and 7="very much improved". 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 24 months, 36 months
Secondary Opioid Consumption in Daily Morphine Equivalents 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, 24 months, 36 months
Secondary Proportion of Patients Who Underwent Lumbar Spinal Surgery During the Study Period 24 months, 36 months
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain